RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Quince Therapeutics - Stock

Quince Therapeutics Net Income 2024

Quince Therapeutics Net Income

-31.39 M USD

Ticker

QNCX

ISIN

US22053A1079

WKN

A2PHHD

In 2024, Quince Therapeutics's profit amounted to -31.39 M USD, a -39.25% increase from the -51.66 M USD profit recorded in the previous year.

The Quince Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2023-
2022-
2021-
2020-
2019-
2018-
2017-

Quince Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Quince Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Quince Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Quince Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Quince Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Quince Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Quince Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Quince Therapeutics’s growth potential.

Quince Therapeutics Revenue, EBIT and net profit per share

DateQuince Therapeutics RevenueQuince Therapeutics EBITQuince Therapeutics Net Income
20230 undefined-28.72 M undefined-31.39 M undefined
20220 undefined-51.19 M undefined-51.66 M undefined
20210 undefined-90.32 M undefined-89.95 M undefined
20200 undefined-78.89 M undefined-76.85 M undefined
20190 undefined-39.17 M undefined-36.98 M undefined
20180 undefined-12.12 M undefined-12.48 M undefined
20170 undefined-10.37 M undefined-12.24 M undefined

Quince Therapeutics stock margins

The Quince Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Quince Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Quince Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Quince Therapeutics's sales revenue. A higher gross margin percentage indicates that the Quince Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Quince Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Quince Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Quince Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Quince Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Quince Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Quince Therapeutics Margin History

Quince Therapeutics Gross marginQuince Therapeutics Profit marginQuince Therapeutics EBIT marginQuince Therapeutics Profit margin
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Quince Therapeutics Aktienanalyse

What does Quince Therapeutics do?

Cortexyme Inc. is a biotechnology company specializing in the development of therapies for degenerative diseases of the nervous system, particularly Alzheimer's disease. The company was founded in 2012 in South San Francisco by Casey Lynch and Stephen Dominy and has since become a leading company in this field. The origin of Cortexyme stems from the discovery of a new bacteria, Porphyromonas gingivalis (P. gingivalis), made by Lynch, the CEO of Cortexyme. He found that P. gingivalis is present in the vicinity of brain plaques in Alzheimer's patients. This discovery meant that Cortexyme had opportunities to develop prevention and treatment options for degenerative diseases of the nervous system. Cortexyme's business model is based on a combination of R&D (research and development) and precision medicine, enabling them to develop personalized therapy approaches. The company is working to specifically target therapeutic molecules against bacteria associated with Alzheimer's and develop biological solutions that target the bacteria. Cortexyme collaborates with a range of specialists, scientists, and university laboratories to conduct their research. The company also has its own research department focused on the discovery of therapeutics to inhibit or eliminate the growth of P. gingivalis. The company has various divisions focusing on the discovery and development of therapeutics. One division focuses on developing biomarkers to aid the diagnosis of Alzheimer's. Another division is developing targeted antibiotics against P. gingivalis, while a third division focuses on developing therapeutics that inhibit the breakdown of bacteria and plaque in the brain. Cortexyme has also developed several products, including the Alzheimer's drug program Atuzaginstat (COR388), which is currently in Phase III of clinical development. Atuzaginstat aims to inhibit P. gingivalis and has the potential to provide hope to terminally ill Alzheimer's patients. Cortexyme is also working on other products, including COR569 to combat inflammation associated with cognitive decline and COR271 to eliminate bacteria that promote brain inflammation. Overall, Cortexyme has taken a new direction in the exploration of Alzheimer's treatment by investigating the role of bacteria in the disease and developing new therapeutic approaches. The company has positioned itself as a leader in Alzheimer's research and will continue to work on developing innovative therapies and prevention strategies that improve the quality of life for Alzheimer's patients and enhance hope for a cure. Quince Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Quince Therapeutics's Profit Margins

The profit margins of Quince Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Quince Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Quince Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Quince Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Quince Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Quince Therapeutics Stock

How much profit has Quince Therapeutics made this year?

Quince Therapeutics has made -31.39 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -39.25% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Quince Therapeutics publish its earnings?

Quince Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Quince Therapeutics?

The profits of Quince Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Quince Therapeutics?

You can learn more about the earnings of Quince Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Quince Therapeutics pay?

Over the past 12 months, Quince Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Quince Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Quince Therapeutics?

The current dividend yield of Quince Therapeutics is .

When does Quince Therapeutics pay dividends?

Quince Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Quince Therapeutics?

Quince Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Quince Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Quince Therapeutics located?

Quince Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Quince Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Quince Therapeutics from 7/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.

When did Quince Therapeutics pay the last dividend?

The last dividend was paid out on 7/4/2024.

What was the dividend of Quince Therapeutics in the year 2023?

In the year 2023, Quince Therapeutics distributed 0 USD as dividends.

In which currency does Quince Therapeutics pay out the dividend?

The dividends of Quince Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Quince Therapeutics

Our stock analysis for Quince Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quince Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.